A recent survey showed correlation between the severity of atopic dermatitis and the negative impacts on family life.
Atopic dermatitis in pediatric patients leads to negative effects on physical, economic, social, and emotional aspects of family life, according to a recent study.
A cross-sectional, web-based survey was administered to children and adolescents aged 6 months to under 18 years and their parents or caregivers across 18 countries encompassing North America, Latin America, Europe, Middle East/Eurasia, and East Asia. These children and adolescents had been identified with atopic dermatitis by the International Study of Asthma and Allergies in Childhood criteria.
The Patient-Oriented Eczema Measure and the Patient Global Assessmentwas used to determine the severity of each case. Finally, the impact on families’ lives was determined through the Dermatitis Family Impact questionnaire. The 7465 pairs of pediatric patients surveyed were divided into subscales based on the severity of atopic dermatitis.
Subscale scores with a greater severity of atopic dermatitis reported a greater negative impact on family life in every aspect, alongside greater sleep and tiredness. Parents missed more workdays and spent more time on childcare in more severe cases. Trends did not change between age groups.
Reference
Barbarot S, Silverberg JI, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. J Pediatr. 2022;246:220-226.e5. doi:10.1016/j.jpeds.2022.04.027
Tapinarof cream 1% demonstrates efficacy in atopic dermatitis patients with skin of color
March 8th 2024Data from a pair of identical, phase 3, double-blind, randomized, and vehicle-controlled trials were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California.
Roflumilast cream 0.15% for atopic dermatitis demonstrates strong individual patient response data
January 16th 2024According to new pooled individual patient responses, roflumilast cream 0.15% treatment led nearly 92% of individuals to achieve a measurable improvement in the Eczema Area and Severity Index.